- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06257277
An Observational Study to Collect Information on the Safety of Gadolinium-Based Contrast Agents in Patients in India
Active Surveillance of the Safety of Gadolinium-based Contrast Agent(s) in India
This is an observational study in which data from patients undergoing enhanced MRI using gadolinium based agents (GBCAs) are collected and studied.
An MRI is a test that uses strong magnets and radio waves to make detailed pictures of the inside of the body. The contrast agents commonly used in MRI are gadolinium based contrast agents (GBCAs). GBCAs contain a "rare earth" element called gadolinium (Gd), which helps to increase the signal intensity and contrast in MRI.
GBCAs have been used worldwide for MRI scans. GBCAs are generally considered safe. In some cases, there have been reports of mild to moderate side effects. There have also been reports indicating that small traces of Gd might stay in the body for an extended period after scans. However, there is no clear evidence that this causes any serious or long term problems in patients with normal kidney function.
There are different brands of GBCAs such as Gadovist and Magnevist. Knowledge about the safety of Gadovist and Magnevist in the Indian population is limited.
This study aims to enhance the currently available information on GBCAs and gather more information on the safety of Gadovist and Magnevist in the Indian population during GBCA enhanced MRI procedures in routine practice.
To do this, researchers will collect the following information:
- any possible medical problems occurring immediately after receiving GBCAs (Gadovist and Magnevist), and after 4 and 12 weeks of receiving GBCAs
- frequency of reporting medical problems after the use of GBCAs (Gadovist and Magnevist)
Patients will be asked to take part in the study only after confirming that they need a GBCA enhanced MRI, and the GBCA brand is already identified.
Data will be collected from February 2024 to September 2024. Healthcare professionals will collect safety data from selected sites which frequently conduct GBCA enhanced MRIs for patients who have not received GBCAs before.
Every patient scheduled for an MRI with contrast agents will be followed up at approximately 4 and 12 weeks after the GBCA enhanced MRI.
In this study, only safety data from routine practice are collected.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Bayer Clinical Trials Contact
- Phone Number: (+)1-888-84 22937
- Email: clinical-trials-contact@bayer.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- GBCA-naïve male/female patients of at least 18 years of age.
- willing to participate in the active surveillance and agree to be contacted by phone after 6 (±2) weeks after the MR scan for brief interviews.
Exclusion Criteria:
- None.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients require GBCA-enhanced MRI
Patients who are scheduled to undergo magnetic resonance imaging (MRI) with gadolinium-based contrast agent (GBCA) enhancement as per routine clinical practice.
|
GBCAs are given per routine clinical practice.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of adverse events reported after use of branded gadolinium-based contrast agent (GBCA).
Time Frame: Immediately post dose and at 6 (±2) weeks post dose
|
Immediately post dose and at 6 (±2) weeks post dose
|
Number for participants with adverse events after use of a branded GBCA
Time Frame: From injection of GBCAs up to 6 (±2) weeks
|
From injection of GBCAs up to 6 (±2) weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 22584
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contrast Enhancement in Magnetic Resonance Imaging
-
BayerCompletedContrast Enhancement in Magnetic Resonance ImagingUnited States
-
BayerRecruitingChildren | Contrast Enhancement in Magnetic Resonance ImagingUnited States, Japan, China, Italy, Czechia, Canada, Poland, Argentina, Bulgaria, Belgium, Germany, Sweden, Hungary
-
BayerCompletedHealthy Volunteers | Contrast Enhancement in Magnetic Resonance ImagingChina
-
BayerCompletedHealthy Volunteers | Contrast Enhancement in Magnetic Resonance ImagingJapan
-
BayerRecruitingContrast Enhancement in Magnetic Resonance Imaging | Central Nervous System PathologyFrance, Turkey, Czechia, China, Japan, United States, United Kingdom, Italy, Korea, Republic of, Germany, Bulgaria, Hungary, Argentina, Canada, Sweden
-
BayerRecruitingContrast Enhancement in Magnetic Resonance Imaging | Non-central Nervous System PathologyUnited States, Sweden, Japan, Czechia, China, Hungary, Poland, Italy, United Kingdom, Turkey, Korea, Republic of, Germany, Taiwan, France, Argentina, Bulgaria, Canada
-
BayerCompleted
-
BayerCompletedContrast Enhancement in Magnetic Resonance ImagingUnited States
-
Vanderbilt University Medical CenterChildren's Hospital of Philadelphia; GuerbetCompletedMagnetic Resonance Imaging Contrast AgentsUnited States
-
Yunus EmreNot yet recruitingSedation Complication | Magnetic Resonance Imaging Contrast Media Adverse Reaction